UK Market-Entry Strategy

We help technology companies understand the UK health and care landscape, including adoption barriers, stakeholder priorities, decision routes, partnership options and routes to scale.

Evidence and Pilot Strategy
We help shape real-world pilots and evidence programmes that are relevant to providers, operators, NHS partners, investors and strategic buyers.

Workflow and Pathway Strategy
We help organisations assess how new technologies could fit into daily workflows, clinical or care pathways, documentation, escalation routes and outcome reporting.

Integration and Digital Strategy
We help identify how prevention and early-detection technologies may need to align with digital care records, care-management systems, reporting tools and partner platforms.

Partnership Development
We help identify where providers, technology companies, digital platforms, NHS partners, sector bodies and strategic commercial partners need to align for adoption to scale.

Medtech and Health-technology Companies

For companies developing prevention, wound-care, thermal imaging, vascular assessment, compression, remote-monitoring or related technologies, SK Photonic provides UK market-entry insight and adoption strategy.
We help companies reduce market-entry risk, avoid weak pilots, and focus resources on adoption models that are more likely to scale.

Care Providers and Operators
For care-home operators, community providers and other care organisations exploring earlier prevention models, SK Photonic helps assess practical fit, evidence requirements, workflow implications and operational readiness.
Our role is not to provide clinical oversight, but to support strategic thinking around adoption, workflow, evidence and implementation.

Digital Care and Health Platforms
For digital care-record, care-management and health-data platforms, SK Photonic helps explore how prevention workflows, data capture and partner integrations could support future care models.
Digital platforms are likely to play an important role in scalable prevention because they sit close to daily documentation, quality reporting, escalation and outcome measurement.

Sector, NHS, and Innovation Partners
For NHS, sector and innovation organisations, SK Photonic supports senior-level discussions on how prevention, early detection and tissue-protection models can be better evidenced, funded and scaled.

Promising technologies often fail to scale because they are treated as products to sell rather than adoption models to build.

SK Photonic helps answer five practical questions:

1. Where is the strongest adoption opportunity, and how should it be approached
2. Who needs to adopt, fund, support or influence it?
3. What evidence will buyers, partners and strategic stakeholders expect?
4. How will it fit into daily workflows, digital systems and outcome reporting?
5. What partnership model gives it the best chance of adoption and scale?

This helps organisations reduce risk, avoid poorly designed pilots, and focus on credible routes to adoption.

SK Photonic is currently focused on prevention, early-detection and tissue-protection technologies across UK health and care settings.

Priority areas include pressure-ulcer prevention, wound care, vascular assessment, compression-related pathways, digital care records, clinical-grade imaging, escalation workflows and real-world evidence.

Care homes are a major area of current work because they combine significant prevention need, operational pressure, workforce constraints and strong potential for earlier detection and better pathway alignment.

A sector-level white paper on pressure-ulcer prevention in UK care homes is in preparation, developed with input from Care England and wider sector stakeholders.

The paper examines the clinical, operational and economic case for earlier prevention and considers why promising technologies often fail to scale without the right evidence, workflow and partnership model.

Selected senior briefings are available ahead of publication.

Request Senior Briefing